Dublin, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The "Glycopeptide Antibiotics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global glycopeptide antibiotics market is set to witness substantial growth, with projections indicating an increase from $3.05 billion in 2022 to $3.29 billion in 2023, reflecting a compound annual growth rate (CAGR) of 7.7%. This growth momentum is expected to persist, propelling the glycopeptide antibiotics market to reach $4.43 billion by 2027, driven by a CAGR of 7.7%.
Leading players in the glycopeptide antibiotics market, including ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, and Bayer AG, are strategically positioned to capitalize on this growth.
Key Reasons to Consider Glycopeptide Antibiotics
- Global Perspective: Gain comprehensive insights across 50+ geographies.
- COVID-19 Impact: Understand the market's response to the pandemic and its ongoing repercussions.
- Geopolitical Factors: Assess the impact of the Russia-Ukraine conflict on agriculture, energy, mineral commodity supply, and its direct and indirect effects on the market.
- Inflation Impact: Measure the consequences of high global inflation on market growth.
- Regional and Country Strategies: Develop tailored strategies based on local data and analysis.
- Identify Growth Segments: Recognize promising segments for investment.
- Competitive Advantage: Outperform competitors using forecast data and market trends.
- Market Shares: Comprehend customer preferences through the latest market shares.
- Performance Benchmarking: Compare performance against key competitors.
- Presentation Enhancement: Elevate internal and external presentations with high-quality data and analysis.
Glycopeptide Antibiotics: A Vital Medical Solution
Glycopeptide antibiotics are a category of antibiotics with structures that include glycosylated cyclic or polycyclic non-ribosomal peptides. They are employed to inhibit the formation of bacterial cell walls. These antibiotics were initially discovered in plant and soil bacteria.
Key Glycopeptide Antibiotics
- Vancomycin: An essential member of the glycopeptide antibiotics family, vancomycin is used to treat colitis resulting from antibiotic therapy. It acts by eradicating microorganisms in the intestines.
- Dalbavancin and Oritavancin: Other significant glycopeptide antibiotics used for various applications.
Diverse Administration Routes
Glycopeptide antibiotics are administered through oral, parenteral, and other routes. They are applied in the treatment of conditions such as skin and structure infections, meningitis, clostridioides difficile infection, enterocolitis, and others. The end-users of glycopeptide antibiotics include hospitals, specialty clinics, home care, and various entities.
Market Research Insights
Our comprehensive report offers detailed glycopeptide antibiotics market statistics, encompassing global market size, regional market shares, key competitors with their market share, finely segmented market categories, emerging market trends, and promising opportunities.
Prominent Trend: Product Innovation
Product innovation is a noteworthy trend in the glycopeptide antibiotics market. Leading companies are dedicated to developing innovative products to fortify their market presence.
Increasing Prevalence of Cancer and Infectious Diseases
The rising incidence of cancer and infectious diseases is expected to be a significant growth driver for the glycopeptide antibiotics market. These antibiotics are employed to treat various infectious disorders caused by antibiotic-resistant bacteria, particularly methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus. Additionally, glycopeptide antibiotics are used to enhance the antitumor effects of radiotherapy in cancer patients by targeting both localized and distant cancer cells.
For instance, in 2022, the US reported approximately 1.9 million new cancer cases and 609,360 cancer-related deaths, underscoring the need for effective treatments. As a result, the demand for glycopeptide antibiotics is expected to rise.
Market Value and Geographical Revenues
The glycopeptide antibiotics market comprises sales of teicoplanin, telavancin, ramoplanin, and related products. Market values represent 'factory gate' values, including the sale of goods by manufacturers to other entities or end customers, along with associated services offered by the goods' creators.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $3.29 billion |
| Forecasted Market Value (USD) by 2027 | $4.43 billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. Glycopeptide Antibiotics Market Characteristics
3. Glycopeptide Antibiotics Market Trends And Strategies
4. Glycopeptide Antibiotics Market - Macro Economic Scenario
4.1. COVID-19 Impact On Glycopeptide Antibiotics Market
4.2. Ukraine-Russia War Impact On Glycopeptide Antibiotics Market
4.3. Impact Of High Inflation On Glycopeptide Antibiotics Market
5. Glycopeptide Antibiotics Market Size And Growth
5.1. Global Glycopeptide Antibiotics Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Glycopeptide Antibiotics Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Glycopeptide Antibiotics Market Segmentation
6.1. Global Glycopeptide Antibiotics Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Vancomycin
- Dalbavancin
- Oritavancin
- Other Drugs
6.2. Global Glycopeptide Antibiotics Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Oral
- Parenteral
- Other Routes
6.3. Global Glycopeptide Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Skin And Structure Infection
- Meningitis
- Clostridioides Difficile Infection
- Enterocolitis
- Other Indications
6.4. Global Glycopeptide Antibiotics Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare
- Other End-Users
7. Glycopeptide Antibiotics Market Regional And Country Analysis
7.1. Global Glycopeptide Antibiotics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Glycopeptide Antibiotics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/vrlwww
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
